Literature DB >> 26181630

TLR4 Deters Perfusion Recovery and Upregulates Toll-like Receptor 2 (TLR2) in Ischemic Skeletal Muscle and Endothelial Cells.

Jia Xu1, Kelly Benabou1, Xiangdong Cui1,2, Marissa Madia1, Edith Tzeng1,2, Timothy Billiar1, Simon Watkins3, Ulka Sachdev1.   

Abstract

Toll-like receptors (TLRs) play an important role in regulating muscle regeneration and angiogenesis in response to ischemia. TLR2 knockout mice exhibit pronounced skeletal muscle necrosis and abnormal vessel architecture after femoral artery ligation, suggesting that TLR2 signaling is protective during ischemia. TLR4, an important receptor in inflammatory signaling, has been shown to regulate TLR2 expression in other systems. We hypothesize that a similar relationship between TLR4 and TLR2 may exist in hindlimb ischemia in which TLR4 upregulates TLR2, a mediator of angiogenesis and perfusion recovery. We examined the expression of TLR2 in unstimulated and in TLR-agonist treated endothelial cells (ECs). TLR2 expression (low in control ECs) was upregulated by lipopolysaccharide, the danger signal high mobility group box-1, and hypoxia in a TLR4-dependent manner. Endothelial tube formation on Matrigel as well as EC permeability was assessed as in vitro measures of angiogenesis. Time-lapse imaging demonstrated that ECs lacking TLR4 formed more tubes, whereas TLR2 knockdown ECs exhibited attenuated tube formation. TLR2 also mediated EC permeability, an initial step during angiogenesis, in response to high-mobility group box-1 (HMGB1) that is released by cells during hypoxic injury. In vivo, ischemia-induced upregulation of TLR2 required intact TLR4 signaling that mediated systemic inflammation, as measured by local and systemic IL-6 levels. Similar to our in vitro findings, vascular density and limb perfusion were both enhanced in the absence of TLR4 signaling, but not if TLR2 was deleted. These findings indicate that TLR2, in the absence of TLR4, improves angiogenesis and perfusion recovery in response to ischemia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26181630      PMCID: PMC4656200          DOI: 10.2119/molmed.2014.00260

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  41 in total

1.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

Authors:  Robert J Lederman; Farrell O Mendelsohn; R David Anderson; Jorge F Saucedo; Alan N Tenaglia; James B Hermiller; William B Hillegass; Krishna Rocha-Singh; Thomas E Moon; M J Whitehouse; Brian H Annex
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine.

Authors:  Stefania Mitola; Mirella Belleri; Chiara Urbinati; Daniela Coltrini; Bianca Sparatore; Marco Pedrazzi; Edon Melloni; Marco Presta
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

3.  Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial.

Authors:  Richard J Powell; John Dormandy; Michael Simons; Ryuichi Morishita; Brian H Annex
Journal:  Vasc Med       Date:  2004-05       Impact factor: 3.239

4.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

5.  High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism.

Authors:  Federico Biscetti; Giuseppe Straface; Raimondo De Cristofaro; Stefano Lancellotti; Paola Rizzo; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Kensuke Egashira; Giulia De Angelis; Giovanni Ghirlanda; Andrea Flex
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

6.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

7.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

8.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

9.  Association of interleukin-6 signalling with the muscle stem cell response following muscle-lengthening contractions in humans.

Authors:  Bryon R McKay; Michael De Lisio; Adam P W Johnston; Ciara E O'Reilly; Stuart M Phillips; Mark A Tarnopolsky; Gianni Parise
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

10.  Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.

Authors:  Roberta Palumbo; Maurilio Sampaolesi; Francesco De Marchis; Rossana Tonlorenzi; Sara Colombetti; Anna Mondino; Giulio Cossu; Marco E Bianchi
Journal:  J Cell Biol       Date:  2004-01-26       Impact factor: 10.539

View more
  11 in total

1.  Ager Deletion Enhances Ischemic Muscle Inflammation, Angiogenesis, and Blood Flow Recovery in Diabetic Mice.

Authors:  Raquel López-Díez; Xiaoping Shen; Gurdip Daffu; Md Khursheed; Jiyuan Hu; Fei Song; Rosa Rosario; Yunlu Xu; Qing Li; Xiangmei Xi; Yu Shan Zou; Huilin Li; Ann Marie Schmidt; Shi Fang Yan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-22       Impact factor: 8.311

2.  Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels.

Authors:  J Góralska; U Raźny; A Polus; J Stancel-Możwiłło; M Chojnacka; A Gruca; A Zdzienicka; A Dembińska-Kieć; B Kieć-Wilk; B Solnica; M Malczewska-Malec
Journal:  Int J Obes (Lond)       Date:  2017-12-13       Impact factor: 5.095

3.  Tlr2 on Bone Marrow and Non-Bone Marrow Derived Cells Regulates Inflammation and Organ Injury in Cooperation with Tlr4 During Resuscitated Hemorrhagic Shock.

Authors:  Sebastian Korff; Patricia Loughran; Changchun Cai; Jie Fan; Greg Elson; Limin Shang; Susana Salgado Pires; Yi Shan Lee; Jesse Guardado; Melanie Scott; Timothy R Billiar
Journal:  Shock       Date:  2016-11       Impact factor: 3.454

Review 4.  Biological and pathophysiological roles of end-products of DHA oxidation.

Authors:  Valentin P Yakubenko; Tatiana V Byzova
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-10-03       Impact factor: 4.698

5.  TLR4-SIRT3 Mechanism Modulates Mitochondrial and Redox Homeostasis and Promotes EPCs Recruitment and Survival.

Authors:  Xiaotian Wang; Weidong Yao; Meihui Wang; Junhui Zhu; Liang Xia
Journal:  Oxid Med Cell Longev       Date:  2022-07-04       Impact factor: 7.310

6.  TLR4 activation inhibits the proliferation and osteogenic differentiation of skeletal muscle stem cells by downregulating LGI1.

Authors:  Haiying Tao; Xiaoyan Tang; Hai Tao
Journal:  J Physiol Biochem       Date:  2022-03-16       Impact factor: 5.080

7.  Ligation of free HMGB1 to TLR2 in the absence of ligand is negatively regulated by the C-terminal tail domain.

Authors:  Hannah Aucott; Agnieszka Sowinska; Helena Erlandsson Harris; Peter Lundback
Journal:  Mol Med       Date:  2018-05-04       Impact factor: 6.354

8.  Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.

Authors:  Ulka Sachdev; Ricardo Ferrari; Xiangdong Cui; Abish Pius; Amrita Sahu; Michael Reynolds; Hong Liao; Ping Sun; Sunita Shinde; Fabrisia Ambrosio; Sruti Shiva; Patricia Loughran; Melanie Scott
Journal:  Mol Med       Date:  2020-07-08       Impact factor: 6.354

9.  Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia.

Authors:  Sachiko Nishimoto; Kunduziayi Aini; Daiju Fukuda; Yasutomi Higashikuni; Kimie Tanaka; Yoichiro Hirata; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Michio Shimabukuro; Masataka Sata
Journal:  Front Cardiovasc Med       Date:  2018-10-16

Review 10.  The Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial Disease.

Authors:  Jun Xu; Ulka Sachdev
Journal:  J Immunol Res       Date:  2016-02-21       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.